telmisartan

telmisartan
Name	Telmisartan
Tradenames	Micardis, Pritor, other
Pregnancy category	D (later in pregnancy)
Legal status	Prescription-only
Routes of administration	Oral
Bioavailability	~50%
Protein bound	~99.5%
Metabolism	Minimal hepatic (glucuronidation)
Elimination half-life	~24 hours
Excretion	Feces and urine

telmisartan

Telmisartan is an angiotensin II receptor blocker used primarily to treat hypertension and reduce cardiovascular risk. It is prescribed for adults with essential hypertension and for cardiovascular risk reduction in selected populations following guideline recommendations. Developed in the 1990s and marketed with global regulatory approval, telmisartan is part of a therapeutic class that includes several widely used antihypertensives.

Medical uses

Telmisartan is indicated for treatment of essential hypertension and for cardiovascular risk reduction in patients with high cardiovascular risk profiles such as those with a history of myocardial infarction, stroke, or peripheral artery disease. Major guideline bodies like the World Health Organization, American Heart Association, European Society of Cardiology, and National Institute for Health and Care Excellence include angiotensin II receptor blockers among first-line options alongside recommendations from national agencies such as the Food and Drug Administration and the European Medicines Agency. Clinical outcome trials and landmark studies comparing agents have informed practice in institutions such as Mayo Clinic, Johns Hopkins Hospital, and Cleveland Clinic.

Pharmacology

Telmisartan is a selective antagonist of the angiotensin II type 1 (AT1) receptor, inhibiting vasoconstrictive and aldosterone-secreting effects mediated by angiotensin II. Mechanistically it acts on the renin–angiotensin–aldosterone system; major research groups at institutions like Harvard Medical School, Karolinska Institutet, and Imperial College London have characterized ARB pharmacodynamics. It differs from angiotensin-converting enzyme inhibitors evaluated in trials by lacking kinase II inhibition and therefore does not typically cause bradykinin-mediated cough seen in studies from centers such as King's College London and Stanford University. Comparative pharmacology involving agents like losartan, valsartan, and candesartan has been explored in multicenter trials coordinated by organizations including the World Heart Federation and the European Medicines Agency.

Dosage and administration

Typical starting doses for adults are informed by randomized controlled trials and prescribing information approved by regulatory agencies; common regimens use once-daily oral dosing due to a long elimination half-life. Dosing adjustments are advised in renal impairment and by consensus statements from societies like the American Society of Nephrology and the European Renal Association–European Dialysis and Transplant Association. Hospital formularies at institutions such as Massachusetts General Hospital and Mount Sinai Hospital provide protocols for initiation, uptitration, and monitoring in special populations including the elderly and those on concomitant cardiovascular therapies developed in collaboration with groups like the American College of Cardiology.

Adverse effects

Common adverse effects reported in clinical trials and postmarketing surveillance include dizziness, hypotension, and gastrointestinal symptoms; major safety reviews by agencies such as the Food and Drug Administration and the European Medicines Agency list renal impairment and hyperkalemia as clinically important risks. Unlike ACE inhibitors highlighted in studies from Cleveland Clinic and Johns Hopkins Hospital, telmisartan is less associated with cough but can still precipitate angioedema in rare cases, an adverse event monitored by pharmacovigilance centers including the Uppsala Monitoring Centre. Warnings for use in pregnancy reflect teratogenic risk assessed by organizations like the World Health Organization and national teratology information services.

Interactions

Telmisartan has clinically relevant interactions with potassium-sparing agents and potassium supplements, nonsteroidal anti-inflammatory drugs catalogued by entities such as the European Medicines Agency and the Food and Drug Administration, and other antihypertensives including agents studied at Johns Hopkins Hospital and Mayo Clinic. Concomitant use with renin–angiotensin system inhibitors increases risk of renal dysfunction and hyperkalemia, a concern addressed in position papers from the American Heart Association and the European Society of Cardiology. Drug interaction resources maintained by institutions like the British National Formulary and UpToDate provide detailed guidance.

Pharmacokinetics

Telmisartan shows high plasma protein binding and a long terminal half-life supporting once-daily dosing; these properties were characterized in pharmacokinetic studies conducted by pharmaceutical researchers and academic centers including University of California, San Francisco and University College London. It undergoes minimal hepatic metabolism via glucuronidation rather than cytochrome P450 oxidation, limiting some classic P450-mediated interactions described in reviews from Johns Hopkins University and Karolinska Institutet. Excretion occurs mainly in feces with minor renal elimination, a profile summarized in drug monographs used by hospital pharmacies at Massachusetts General Hospital and regulatory summaries from the European Medicines Agency.

Chemistry and formulation

Chemically, telmisartan is a nonpeptide molecule with a biphenyl-tetrazole structure characteristic of many angiotensin II receptor blockers; medicinal chemistry contributions from industrial research groups and academic collaborations at institutions such as Eli Lilly and Company, Boehringer Ingelheim, and AstraZeneca informed its design. Formulations include immediate-release oral tablets in various strengths marketed globally, with production and quality standards overseen by regulatory authorities including the Food and Drug Administration and national agencies like the Medicines and Healthcare products Regulatory Agency.

History and society

Developed in the 1990s, telmisartan was introduced to market after clinical development programs and regulatory reviews by bodies such as the Food and Drug Administration and the European Medicines Agency; major pharmaceutical firms and research consortia played roles in trials published in journals affiliated with institutions such as New England Journal of Medicine and The Lancet. Its adoption in clinical practice has been influenced by guideline statements from the American Heart Association, European Society of Cardiology, and national health services including the National Health Service (England), impacting prescribing patterns in hospitals like Cleveland Clinic and healthcare systems worldwide. Patent and access issues were navigated through intellectual property frameworks administered by organizations like the United States Patent and Trademark Office and the European Patent Office.

Category:Angiotensin II receptor antagonists